LEADER 04427nam 22003491i 4500

001 49484

003 NhCcYBP

005 20240430191638.1

006 m |o d |

007 cr |n|||||||||

008 240430s2022 sz a ob 000 0 eng d

020 $a9783030874803 (electronic bk.)

020 $a303087480X (electronic bk.)

020 $z9783030874797

020 $z3030874796

035 $aebs3259241

040 $aNhCcYBP$cNhCcYBP

041 $aeng

050 4$aQP364.5$b.G58 2022

060 4$aWL 301

082 04$a612.8$223

245 00$aGlutamate and neuropsychiatric disorders :$bcurrent and emerging treatments /$cZoran M. Pavlovic, editor.

264 1$aCham, Switzerland :$bSpringer,$c[2022]

300 $a1 online resource (xxxv, 600 pages) :$billustrations (black and white, and colour.

336 $atext$btxt$2rdacontent

337 $acomputer$bc$2rdamedia

338 $aonline resource$bcr$2rdacarrier

504 $aIncludes bibliographical references.

505 00$tTreatments Against Glutamatergic Excitotoxicity in Ischemic Stroke --$tDefinitions and Concepts of Stress --$tRole of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response --$tCurrent Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders --$tThe Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments --$tGlutamate in Migraine Neurobiology and Treatment --$tAstrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia --$tThe Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder --$tCNS Glutamate in Impulsive Aggression --$tGlutamatergic Treatments for Parkinsons' Disease --$tThe Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression --$tGlutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease --$tModulation of Glutamate for Chronic Pain Management --$tPharmacological Role of Glutamate Transporters in Substance Use Disorders --$tGlutamate in Multiple Sclerosis: From Pathophysiology to Treatments --$tThe Role of Glutamate Dysregulation in the Etiology of ADHD --$tGlutamate, Glutamatergic Drugs and Schizophrenia --$tGlutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy --$tGlutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies --$tModulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders. Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke -- Definitions and Concepts of Stress -- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response -- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders -- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments -- Glutamate in Migraine Neurobiology and Treatment -- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia -- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder -- CNS Glutamate in Impulsive Aggression -- Glutamatergic Treatments for Parkinsons' Disease -- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression -- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease -- Modulation of Glutamate for Chronic Pain Management -- Pharmacological Role of Glutamate Transporters in Substance Use Disorders -- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments -- The Role of Glutamate Dysregulation in the Etiology of ADHD -- Glutamate, Glutamatergic Drugs and Schizophrenia -- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy -- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies -- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders.

533 $aElectronic reproduction.$bIpswich, MA$nAvailable via World Wide Web.

588 $aDescription based on print version record.

650 0$aNeural transmission.$388405

650 0$aGlutamic acid$xPhysiological effect.$392369

650 0$aNeurobehavioral disorders$xTreatment.$392370

650 12$aCentral Nervous System Diseases$xdrug therapy$312977

650 22$aMental Disorders$xdrug therapy$313404

650 22$aGlutamates$xtherapeutic use$392371

650 22$aExcitatory Amino Acid Agents$392373

650 22$aNerve Growth Factors$xphysiology$392374

650 2$aSynaptic Transmission$392375

700 1 $aPavlovi�c, Zoran M.$c(Psychiatrist),$eeditor.$392376

710 2 $aEBSCOhost$387894

776 08$cOriginal$z9783030874797$z3030874796

856 40$uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3259241$zClick to View (限總院院內)

網路資源：

• Click to View (限總院院內)